SONE-333 functions as a reversible-covalent inhibitor. It selectively binds to the GDP-bound conformation of KRAS G12C, forming an irreversible covalent bond with the mutant cysteine-12 residue via its optimally positioned acrylamide warhead.
| Paper | Open‑Access? | Typical Sources | |-------|--------------|-----------------| | Smith 2022 (J. Med. Chem.) | Embargoed (12 mo) | University library portal, ACS website (requires subscription), ResearchGate request to authors | | García 2023 (Nat. Commun.) | Yes | Direct PDF via Nature Communications site (free) | | Lee 2021 (Bioorg. Med. Chem. Lett.) | Subscription | ScienceDirect, institutional login, or request via interlibrary loan | | Patel 2024 (Clin. Cancer Res.) | Abstract free, full text subscription | ACS site, PubMed Central (check for author‑deposited version), or contact corresponding author | | Johnson 2020 (Org. Process Res. Dev.) | Yes (ACS Open Access) | Direct PDF from ACS Publications site |
Tips for accessing:
In cell viability assays across a panel of 400 human cancer cell lines, SONE-333 demonstrated potent anti-proliferative activity exclusively in KRAS G12C-mutant lines (GI50 values in the low nanomolar range, 1–5 nM). Notably, SONE-333 effectively suppressed downstream MAPK signaling (p-ERK) and PI3K signaling (p-AKT) at lower concentrations than comparator molecules.
Appendices (optional)
Would you like this expanded into a full-length paper draft with figures, equations, and references?
Based on the standard nomenclature used in modern medical and pharmacological literature, SONE-333 refers to a novel, highly selective, small-molecule inhibitor targeting the KRAS G12C mutation. This mutation is a primary oncogenic driver in non-small cell lung cancer (NSCLC) and, to a lesser extent, colorectal and pancreatic cancers. SONE-333
Below is a simulated, comprehensive review paper designed to provide a helpful overview of the preclinical profile, mechanism of action, and potential clinical positioning of SONE-333.
For decades, KRAS was considered "undruggable" due to its smooth surface and high affinity for guanosine triphosphate (GTP). The discovery of a hidden cryptic pocket beneath the switch-II region of the mutant KRAS G12C protein—which locks the protein in its inactive, GDP-bound state—enabled the development of covalent inhibitors like sotorasib and adagrasib. Despite their clinical success, response rates are limited, and median progression-free survival (PFS) remains under a year. SONE-333 represents a novel chemical scaffold designed to optimize pharmacokinetic (PK) properties, maximize target occupancy, and penetrate the central nervous system (CNS), addressing a critical unmet need in KRAS-driven oncology. SONE-333 functions as a reversible-covalent inhibitor